Show an ad over header. AMP

The questions the COVID-19 vaccine trials still need to answer

COVID-19 vaccines are being developed at record speed, but some experts fear the accelerated regulatory process could interfere with ongoing research about the vaccines.

Why it matters: Even after the first COVID-19 vaccines are deployed, scientific questions will remain about how they are working and how to improve them.


The big questions: The first is whether people can have rare or delayed side effects, which could be detected in long-term trials with millions of participants.

  • "Most vaccine side effects do occur in the short term," Kathleen Neuzil, director of the Center for Vaccine Development and Global Health, said at an Infectious Diseases Society of America briefing Thursday. "But we don't know a lot about COVID, and we don't know a lot about the long-term consequences of COVID."
  • The tens of thousands of people currently enrolled in clinical trials in the U.S. will be tracked for at least two years to determine whether the vaccines pose any rare or delayed side effects.

How long immunity through vaccination lasts, and whether vaccines will stop transmission of the virus or just prevent people from becoming sick, are also open questions.

  • "It still has to be proven if the vaccine can flatten the curve and eradicate the virus in its own right," says Mark Poznansky, director of the Vaccine & Immunotherapy Center at Massachusetts General Hospital, adding that the immunology of the virus isn't completely understood.
  • On the other hand, Neuzil said early efficacy reports suggest "if we can get enough vaccine out there, we can have an impact on this pandemic very, very quickly."

What's next: The Food and Drug Administration is considering authorizing vaccines for emergency use — a faster process than full approval. Moderna and Pfizer have already submitted their requests for an emergency use authorization.

  • But some experts are afraid that once the FDA begins granting those EUAs, it'll be harder to maintain strict, placebo-controlled clinical trials to answer these l0nger-term questions.
  • Some argue that continuing to administer a placebo when a vaccine is available would be unethical, and there's also a concern that patients will leave trials where they might be getting a placebo.

The big picture: The accelerated development timeline means that "this question of whether it is appropriate to continue someone on placebo kicks in earlier than usual," says bioethicist David Wendler of the NIH's Clinical Center.

  • Trials that are already underway could likely justify continuing to use placebos if participants know they have a choice and consent to still potentially receiving a placebo, Wendler and his colleagues argue today in the journal Science.
  • Developers could help keep their trials going by guaranteeing that people who receive placebos will get a vaccine once their participation in the study is complete, they write.
  • Future trials would likely test two vaccines against each other, rather than testing one against a placebo, though there are limits to that approach.

What to watch: The FDA is set to meet on Dec. 10 to discuss Pfizer-BioNTech's EUA.

  • The breadth or narrowness of those EUAs will determine their impact on future research, says Alison Bateman-House, a professor of medical ethics at NYU's Grossman School of Medicine.
  • "If anyone who wants it can get it, you’ve killed the trials."

The bottom line: The EUA "is definitely not the end but hopefully maybe the beginning of the end" of the pandemic, Wendler says. "The question is what more do we need to figure out to get to the end?"

Capitol review panel recommends boosting security with more police, mobile fencing

A panel appointed by Congress to review security measures at the Capitol is recommending several changes, including mobile fencing and a bigger Capitol police force, to safeguard the area after a riotous mob breached the building on Jan 6.

Why it matters: Law enforcement officials have warned there could be new plots to attack the area and target lawmakers, including during a speech President Biden is expected to give to a joint session of Congress.

Keep reading... Show less

Financial fallout from the Texas deep freeze

Texas has thawed out after an Arctic freeze last month threw the state into a power crisis. But the financial turmoil from power grid shock is just starting to take shape.

Why it matters: In total, electricity companies are billions of dollars short on the post-storm payments they now owe to the state's grid operator. There's no clear path for how they will pay — something being watched closely across the country as extreme weather events become more common.

Keep reading... Show less

Chamber of Commerce decides against widespread political ban following Capitol insurrection

The U.S. Chamber of Commerce revealed Friday it won't withhold political donations from lawmakers who simply voted against certifying the presidential election results and instead decide on a case-by-case basis.

Why it matters: The Chamber is the marquee entity representing businesses and their interests in Washington. Its memo, obtained exclusively by Axios, could set the tone for businesses debating how to handle their candidate and PAC spending following the Jan. 6 Capitol attack.

Keep reading... Show less

Scoop: CDC lets child migrant shelters fill to 100% despite COVID concern

The Centers for Disease Control is allowing shelters handling child migrants who cross the U.S.-Mexico border to expand to full capacity, abandoning a requirement they stay near 50% to inhibit the spread of the coronavirus, Axios has learned.

Why it matters: The fact the country's premier health advisory agency is permitting a change in COVID-19 protocols indicates the scale of the immigration crisis. A draft memo obtained by Axios conceded "facilities should plan for and expect to have COVID-19 cases."

Keep reading... Show less

8 Senate Democrats vote against adding $15 minimum wage amendment to COVID relief

Eight Democratic senators on Friday voted against Sen. Bernie Sanders' amendment to ignore a ruling by the Senate parliamentarian and add a $15 minimum wage provision to the $1.9 trillion COVID relief package.

The state of play: The vote was held open for hours on Friday afternoon — even after every senator had voted — due to a standoff in negotiations over the next amendments that the Senate is set to take up.

Keep reading... Show less

CDC: Easing mask mandates, re-opening restaurants led to higher COVID cases, deaths

Easing mask restrictions and on-site dining have increased COVID-19 cases and deaths, according to a study out Friday from the Centers for Disease Control and Prevention.

Why it matters: The report's findings converge with actions from governors this week easing mask mandates and announcing plans to reopen nonessential businesses like restaurants.

Keep reading... Show less

Exclusive: GOP Leader McCarthy asks to meet with Biden about the border

House Minority Leader Kevin McCarthy (R-Calif.) has requested a meeting with President Biden to discuss the rising numbers of unaccompanied migrant children at the U.S.-Mexico border, in a letter sent on Friday.

Why it matters: Biden is facing criticism from the right and the left as agency actions and media reports reveal spiking numbers of migrant children overwhelming parts of the U.S. immigration system. Recent data shows an average of 321 kids being referred to migrant shelters each day, as Axios reported.

Keep reading... Show less

Public desire for vaccine increases to 69%, but with partisan divide

69% of the public intends to get a COVID vaccine or already has, up significantly from 60% in November, according to a report out Friday from the Pew Research Center.

Yes, but: The issue has become even more partisan, with 56% of Republicans who say they want or have already received a coronavirus vaccine compared to 83% of Democrats.

Keep reading... Show less

Insights

mail-copy

Get Goodhumans in your inbox

Most Read

More Stories